RxSight preliminary Q4 2025 revenue ~$32.6M, FY2025 revenue ~$134.5M above guidance; appoints Mark Wilterding CFO

RxSight, Inc.

2025-FY EPS reported -$0.95 revenue$134,479,000

Q4 2025 revenue ~$32.6M; FY2025 revenue ~$134.5M vs prior guidance $125-130M.
LAL procedure volume 28,611 in Q4 (+10% QoQ) and 109,615 in FY2025 (+12% YoY).
Installed LDD base reached 1,134 as of Dec 31, 2025 (25 LDDs sold in Q4).
Cash & short-term investments ~$228.1M as of Dec 31, 2025.
Mark Wilterding appointed CFO effective Jan 11, 2026, replacing Shelley Thunen (consulting role).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.